Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical-stage biopharmaceutical company with a positive outlook due to its large market potential in the treatment of ADHD and anxiety. The company's recent CEO transition may pose risks, but with a strong focus on product development and promising data for their proprietary drugs utilizing the Precision Timed Release (PTR) technology, Cingulate's current valuation is attractive and presents significant upside potential for investors in the biotech industry.

Bears say

Cingulate is a clinical stage biopharmaceutical company with a negative outlook due to its focus on ADHD and anxiety, limited cash on hand until mid-2027, and potential approval and commercialization timeline of mid or late-2026. This could lead to financial difficulties in the interim, as evidenced by the recent Q3 report showing a net loss of $7.3 million and lack of revenue due to its in-development status.

Cingulate (CING) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cingulate (CING) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.